Veeva Q2 revenue, adjusted net income beats estimates

Overview

• Veeva fiscal Q2 2026 rev rises 17% yr/yr to $789.1 mln, beating analyst expectations, per LSEG data

• Adjusted net income for fiscal Q2 beats analyst estimates, per LSEG data

• Co highlights advancements in AI initiatives and strategic partnerships

Outlook

• Veeva sees Q3 revenue between $790 mln and $793 mln

• Company expects Q3 non-GAAP EPS between $1.94 and $1.95

• Veeva projects FY revenue between $3.134 bln and $3.140 bln

• Company anticipates FY non-GAAP EPS of approximately $7.78

Result Drivers

• AI INITIATIVES - Veeva AI and Veeva Data Cloud are enabling transformational change for life sciences, per CEO Peter Gassner

• VAULT CRM MILESTONES - Two top 20 biopharmas went live with Vault CRM, now with over 100 customers, expanding capabilities

• STRATEGIC PARTNERSHIP - Veeva and IQVIA's partnership allows joint customers to use products and services efficiently across commercial and clinical

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 19 "strong buy" or "buy", 11 "hold" and 2 "sell" or "strong sell"

• The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

• Wall Street's median 12-month price target for Veeva Systems Inc is $300.00, about 4.5% above its August 26 closing price of $286.54

• The stock recently traded at 36 times the next 12-month earnings vs. a P/E of 31 three months ago

Press Release: ID:nPn7Nsp6Ka